Trial
NCT00831649
A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Biogen
Collaborators
Elan Pharmaceuticals
Condition
Rheumatoid Arthritis
Intervention
natalizumab
Why stopped
The biological effect seen with natalizumab was not sufficient to warrant further development in RA.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-06-16